505 related articles for article (PubMed ID: 33268306)
1. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children.
Tsai TA; Tsai CK; Kuo KC; Yu HR
J Microbiol Immunol Infect; 2021 Aug; 54(4):557-565. PubMed ID: 33268306
[TBL] [Abstract][Full Text] [Related]
2. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia.
Ding G; Zhang X; Vinturache A; van Rossum AMC; Yin Y; Zhang Y
Eur J Pediatr; 2024 Jul; 183(7):3001-3011. PubMed ID: 38634891
[TBL] [Abstract][Full Text] [Related]
3. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia.
Zhou Y; Wang J; Chen W; Shen N; Tao Y; Zhao R; Luo L; Li B; Cao Q
BMC Infect Dis; 2020 Aug; 20(1):633. PubMed ID: 32847534
[TBL] [Abstract][Full Text] [Related]
4. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.
Cao B; Qu JX; Yin YD; Eldere JV
Clin Respir J; 2017 Jul; 11(4):419-429. PubMed ID: 26365811
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
Lee H; Yun KW; Lee HJ; Choi EH
Expert Rev Anti Infect Ther; 2018 Jan; 16(1):23-34. PubMed ID: 29212389
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan.
Chang CH; Tsai CK; Tsai TA; Wang SC; Lee YC; Tsai CM; Liu TY; Kuo KC; Chen CC; Yu HR
Pediatr Neonatol; 2021 Sep; 62(5):536-542. PubMed ID: 34147432
[TBL] [Abstract][Full Text] [Related]
7. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children.
Lung DC; Yip EK; Lam DS; Que TL
Pediatr Infect Dis J; 2013 Dec; 32(12):1396-9. PubMed ID: 23817339
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of resistance acquisition and treatment of macrolide-resistant
Yang HJ; Song DJ; Shim JY
Korean J Pediatr; 2017 Jun; 60(6):167-174. PubMed ID: 28690643
[No Abstract] [Full Text] [Related]
9. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter?
Yang TI; Chang TH; Lu CY; Chen JM; Lee PI; Huang LM; Chang LY
J Microbiol Immunol Infect; 2019 Apr; 52(2):329-335. PubMed ID: 30341022
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.
Kawai Y; Miyashita N; Yamaguchi T; Saitoh A; Kondoh E; Fujimoto H; Teranishi H; Inoue M; Wakabayashi T; Akaike H; Ogita S; Kawasaki K; Terada K; Kishi F; Ouchi K
Respirology; 2012 Feb; 17(2):354-62. PubMed ID: 22077195
[TBL] [Abstract][Full Text] [Related]
11. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011.
Eshaghi A; Memari N; Tang P; Olsha R; Farrell DJ; Low DE; Gubbay JB; Patel SN
Emerg Infect Dis; 2013; 19(9):1525-7. PubMed ID: 23968896
[TBL] [Abstract][Full Text] [Related]
12. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019.
Lee KL; Lee CM; Yang TL; Yen TY; Chang LY; Chen JM; Lee PI; Huang LM; Lu CY
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):281-291. PubMed ID: 32948415
[TBL] [Abstract][Full Text] [Related]
13. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.
Zhou Y; Zhang Y; Sheng Y; Zhang L; Shen Z; Chen Z
Antimicrob Agents Chemother; 2014; 58(2):1034-8. PubMed ID: 24277047
[TBL] [Abstract][Full Text] [Related]
14. Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy.
Lung DC; Chan YH; Kwong L; Que TL
Hong Kong Med J; 2011 Oct; 17(5):407-9. PubMed ID: 21979480
[TBL] [Abstract][Full Text] [Related]
15. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia.
Morozumi M; Takahashi T; Ubukata K
J Infect Chemother; 2010 Apr; 16(2):78-86. PubMed ID: 20094751
[TBL] [Abstract][Full Text] [Related]
16. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children.
Okada T; Morozumi M; Tajima T; Hasegawa M; Sakata H; Ohnari S; Chiba N; Iwata S; Ubukata K
Clin Infect Dis; 2012 Dec; 55(12):1642-9. PubMed ID: 22972867
[TBL] [Abstract][Full Text] [Related]
17. Outbreak of macrolide-resistant mycoplasma pneumoniae in a primary school in Beijing, China in 2018.
Zhang WZ; Zhang SJ; Wang QY; Li YD; Jing HB; Hu GY; Wu D
BMC Infect Dis; 2019 Oct; 19(1):871. PubMed ID: 31640591
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan.
Wu PS; Chang LY; Lin HC; Chi H; Hsieh YC; Huang YC; Liu CC; Huang YC; Huang LM
Pediatr Pulmonol; 2013 Sep; 48(9):904-11. PubMed ID: 23169584
[TBL] [Abstract][Full Text] [Related]
19. Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.
Chen YC; Hsu WY; Chang TH
Emerg Infect Dis; 2020 Jul; 26(7):1382-1391. PubMed ID: 32568052
[TBL] [Abstract][Full Text] [Related]
20. Multiple-locus variable-number tandem-repeat analysis (MLVA) of macrolide-susceptible and -resistant Mycoplasma pneumoniae in children in Taiwan.
Lu CY; Yen TY; Chang LY; Liau YJ; Liu HH; Huang LM
J Formos Med Assoc; 2020 Oct; 119(10):1539-1545. PubMed ID: 31924377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
